US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lakewood-Amedex Biotherapeutics (Direct Listing)

2.18

-0.0600-2.68%

Volume:26.27K

Turnover:57.33K

Market Cap:5.17M

PE:-0.21

High:2.27

Open:2.20

Low:2.10

Close:2.24

52wk High:98.20

52wk Low:1.66

Shares:2.37M

Float Shares:1.42M

Volume Ratio:0.65

T/O Rate:1.86%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-10.2000

EPS(LYR):-8.3987

ROE:-402.84%

ROA:-139.40%

PB:1.19

PE(LYR):-0.26

Loading ...

Overview Company News Filings

Lakewood-Amedex Q2 FY26 Net Loss Widens to $3.77 Million; R&D Expense More than Doubled to $503,020

Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting

Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting

Lakewood-amedex Biotherapeutics Flags New Press Release Available on Nu-3 Resistance Data

Lakewood-Amedex announces preclinical data from Phase 2a clinical trial

Lakewood-amedex Biotherapeutics Reports Release Available on Nu-3 Gel Preclinical Safety Data

Lakewood-amedex Biotherapeutics - Finalizing Preparation for Phase 2a Trial in Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

THOMSON REUTERS

Lakewood-amedex Biotherapeutics - Nu-3 Well Tolerated at High Doses with Low Systemic Exposure in Preclinical Study

THOMSON REUTERS

Lakewood-amedex Biotherapeutics - Preparing to Enter Phase 2 Clinical Development with Nu-3 for Infected Diabetic Foot Ulcer

THOMSON REUTERS

Lakewood-amedex Names David Armstrong Study Chair for Nu-3 Phase 2a Idfu Trial

Lakewood-Amedex Biotherapeutics announces new patent in Australia

Lakewood-Amedex wins Australia patent for Bisphosphocin antimicrobial compounds

Lakewood-Amedex Biotherapeutics - Announces 1-for-10 Reverse Stock Split of Common Stock - SEC Filing

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics CEO presents at Life Sciences Virtual Investor Forum

Lakewood-Amedex Biotherapeutics building broad antimicrobial platform, CEO says

Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper

Lakewood-Amedex Biotherapeutics issued two new patents

Lakewood-Amedex wins Australia, New Zealand patents for Nu-3 diabetic foot ulcer gel formulation

Lakewood-Amedex Q1 FY26 net loss widens to $923,291

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/LABT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":2.18,"timestamp":1787590611118,"preClose":2.24,"halted":0,"volume":26265,"delay":0,"changeRate":-0.02678571428571431,"floatShares":1415552,"shares":2369700,"eps":-10.199959,"marketStatus":"Trading","change":-0.06,"latestTime":"08-24 13:00:37 EDT","open":2.2,"high":2.2722,"low":2.1,"amount":57328.6155,"amplitude":0.076875,"askPrice":2.2,"askSize":972,"bidPrice":2.11,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-10.199959,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":2.24,"preHourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.24,"latestTime":"09:28 EDT","volume":1059,"amount":2400.443772,"timestamp":1787578082120,"change":-0.04,"changeRate":-0.017857,"amplitude":0.093616},"postHourTrading":{"tag":"盘后","latestPrice":2.18,"preClose":2.24,"latestTime":"19:12 EDT","volume":4097,"amount":9153.5807,"timestamp":1787353959572,"change":-0.06,"changeRate":-0.026786,"amplitude":0.03125},"volumeRatio":0.653845},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":1415552,"roa":"-139.40%","roe":"-402.84%","lyrEps":-8.39872,"volumeRatio":0.653845,"shares":2369700,"dividePrice":0,"high":2.2722,"amplitude":0.076875,"preClose":2.24,"low":2.1,"week52Low":1.66,"pbRate":"1.19","week52High":98.2,"institutionHeld":0,"latestPrice":2.18,"committee":-0.528302,"eps":-10.199959,"divideRate":0,"volume":26265,"delay":0,"ttmEps":-10.199959,"open":2.2,"prevYearClose":80,"prevWeekClose":2.24,"prevMonthClose":2.02,"prevQuarterClose":3.14,"fiveDayClose":2.16,"twentyDayClose":2.5,"sixtyDayClose":7.299},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-08-21","current":-0.219609,"percent":0.905405,"low":-12.282138,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"high":-0.62611,"avg":-2.731171,"sd":3.316371,"marketCap":5189616},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724},{"date":"2026-06-26","current":-1.276597,"twenty":-10.242559,"median":-2.72924,"eighty":-2.388094,"marketCap":4911883},{"date":"2026-07-02","current":-1.116845,"twenty":-7.294845,"median":-2.69016,"eighty":-1.477578,"marketCap":4725718},{"date":"2026-07-10","current":-0.893476,"twenty":-5.58279,"median":-2.580737,"eighty":-1.276597,"marketCap":3780575},{"date":"2026-07-17","current":-0.62611,"twenty":-3.536511,"median":-2.512255,"eighty":-1.062695,"marketCap":2649266},{"date":"2026-07-24","current":-1.03562,"twenty":-3.225364,"median":-2.41344,"eighty":-0.92732,"marketCap":4382030},{"date":"2026-07-31","current":-0.653185,"twenty":-2.937143,"median":-2.34533,"eighty":-0.879262,"marketCap":2763829},{"date":"2026-08-07","current":-0.754716,"twenty":-2.857942,"median":-1.477578,"eighty":-0.80819,"marketCap":3193440},{"date":"2026-08-14","current":-0.78856,"twenty":-2.830251,"median":-1.371504,"eighty":-0.793975,"marketCap":3336643},{"date":"2026-08-21","current":-0.706322,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"marketCap":5189616}],"updateTime":1787550852265},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659110010","title":"Lakewood-Amedex Q2 FY26 Net Loss Widens to $3.77 Million; R&D Expense More than Doubled to $503,020","url":"https://stock-news.laohu8.com/highlight/detail?id=2659110010","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659110010?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:08","pubTimestamp":1786702114,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Q2 FY26 net loss widens to $3.77 million; R&D expense more than doubled to $503,020Lakewood-Amedex posted a net loss of $3.77 million for the quarter ended June 30, 2026, widening from the prior-year period.Operating loss widened to $3.79 million as total operating expenses climbed to $3.79 million.Research and development spending more than doubled to $503,020, driven by higher manufacturing, regulatory and clinical planning for Nu-3 Phase 2a.General and administrative costs jumped to $3.29 million, mainly due to $2.4 million in noncash professional services tied to stock issuance.Series C Convertible Preferred Stock private placement raised about $6.8 million net; common stock began trading on Nasdaq Capital Market on April 23.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2kZSYf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658954040","title":"Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2658954040","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658954040?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:14","pubTimestamp":1786396498,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics announces annual shareholder meetingLakewood-Amedex Biotherapeutics will hold its annual shareholder meeting virtually on Sept. 22, 2026.Shareholders will vote to elect","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL8pvPMK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655939386","title":"Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655939386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655939386?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:33","pubTimestamp":1785443614,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics announces annual shareholder meetingLakewood-Amedex Biotherapeutics will hold its annual stockholder meeting virtually on September 22, 2026.Shareholders will vote on e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL4nbJ9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653577357","title":"Lakewood-amedex Biotherapeutics Flags New Press Release Available on Nu-3 Resistance Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2653577357","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653577357?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:04","pubTimestamp":1784721865,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance dataLakewood-Amedex published a July 22, 2026 release highlighting new resistance data for Nu-3, its Phase 2-ready ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL5F7T3W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651946871","title":"Lakewood-Amedex announces preclinical data from Phase 2a clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651946871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651946871?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:10","pubTimestamp":1784117436,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-announces-preclinical-data-from-phase-2a-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-announces-preclinical-data-from-phase-2a-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","LABT","GDOC","HYLG","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651446850","title":"Lakewood-amedex Biotherapeutics Reports Release Available on Nu-3 Gel Preclinical Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651446850","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651446850?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:05","pubTimestamp":1784117146,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics reports release available on Nu-3 gel preclinical safety dataLakewood-Amedex Biotherapeutics posted preclinical safety data supporting dose selection for a planned Phas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL2m8FqM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651746880","title":"Lakewood-amedex Biotherapeutics - Finalizing Preparation for Phase 2a Trial in Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2651746880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651746880?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:02","pubTimestamp":1784116920,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA67ZBM1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651688854","title":"Lakewood-amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2651688854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651688854?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:02","pubTimestamp":1784116920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA67ZBM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651688014","title":"Lakewood-amedex Biotherapeutics - Nu-3 Well Tolerated at High Doses with Low Systemic Exposure in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2651688014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651688014?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:02","pubTimestamp":1784116920,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA67ZBM1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982078","title":"Lakewood-amedex Biotherapeutics - Preparing to Enter Phase 2 Clinical Development with Nu-3 for Infected Diabetic Foot Ulcer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982078?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:04","pubTimestamp":1783425847,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646287054","title":"Lakewood-amedex Names David Armstrong Study Chair for Nu-3 Phase 2a Idfu Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2646287054","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646287054?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:02","pubTimestamp":1782388973,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex names David Armstrong study chair for Nu-3 Phase 2a iDFU trialLakewood-Amedex named David G. Armstrong as study chair for its Phase 2a trial of Nu-3 in infected diabetic foot ulcers.Ar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL6cxDYz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022363","title":"Lakewood-Amedex Biotherapeutics announces new patent in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022363?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:13","pubTimestamp":1782130429,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced the expansion of the company’s patent portfolio with the issuance of a new patent in Australia pro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-announces-new-patent-in-australia-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-announces-new-patent-in-australia-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024196","title":"Lakewood-Amedex wins Australia patent for Bisphosphocin antimicrobial compounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024196?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:04","pubTimestamp":1782129866,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics secured an Australia composition-of-matter patent covering new Bisphosphocin compounds for high-need antimicrobial infections.IP Australia issued the patent on March 5, 2026, titled “Antimicrobial Compounds, Compositions, and Uses Thereof.”Coverage targets compounds under evaluation for complicated urinary tract infections, pulmonary infections.Portfolio totals 72 granted patents, 29 pending patents across major markets including the US, Europe, China, Japan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL56kBD9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644747205","title":"Lakewood-Amedex Biotherapeutics - Announces 1-for-10 Reverse Stock Split of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644747205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644747205?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:41","pubTimestamp":1781710915,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42P0CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754791","title":"Lakewood-Amedex Biotherapeutics CEO presents at Life Sciences Virtual Investor Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754791?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:04","pubTimestamp":1781611444,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics will present at the Life Sciences Virtual Investor Forum on June 25, 2026, at 11:30 a.m. EDT.CEO Kelvin Cooper is scheduled to discuss the company’s growth strategy, including its Nu-3 topical gel program for infected diabetic foot ulcers.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL2tcnsK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639167489","title":"Lakewood-Amedex Biotherapeutics building broad antimicrobial platform, CEO says","url":"https://stock-news.laohu8.com/highlight/detail?id=2639167489","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639167489?lang=en_us&edition=fundamental","pubTime":"2026-05-30 02:11","pubTimestamp":1780078300,"startTime":"0","endTime":"0","summary":"14:00 EDT Lakewood-Amedex Biotherapeutics (LABT) building broad antimicrobial platform, CEO says Published first on TheFly – the ultimate source fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-building-broad-antimicrobial-platform-ceo-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-building-broad-antimicrobial-platform-ceo-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639674811","title":"Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper","url":"https://stock-news.laohu8.com/highlight/detail?id=2639674811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639674811?lang=en_us&edition=fundamental","pubTime":"2026-05-30 02:05","pubTimestamp":1780077931,"startTime":"0","endTime":"0","summary":"In an exclusive interview, Lakewood‑Amedex Biotherapeutics (LABT) CEO Kelvin Cooper spoke with The Fly about the company, going public, its Bisphos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/meet-lakewood-amedex-biotherapeutics-fly-exclusive-with-ceo-kelvin-cooper-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/meet-lakewood-amedex-biotherapeutics-fly-exclusive-with-ceo-kelvin-cooper-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1992135472.HKD","BK4198","LABT","LU2211815571.USD","LU1992135399.USD","LU2272731782.SGD","LU2272731600.USD","GB00BDT5M118.USD","COO","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638891926","title":"Lakewood-Amedex Biotherapeutics issued two new patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2638891926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638891926?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:34","pubTimestamp":1779892465,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced an expansion of its global intellectual property portfolio with the issuance of two patents, one e...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-issued-two-new-patents-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-issued-two-new-patents-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638077335","title":"Lakewood-Amedex wins Australia, New Zealand patents for Nu-3 diabetic foot ulcer gel formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2638077335","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638077335?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:04","pubTimestamp":1779883444,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics secured new gel-formulation patents for Bisphosphocin Nu-3 in Australia and New Zealand.New Zealand granted patent 759577 on Feb. 3, 2026; Australia granted patent 2024202211 on March 19, 2026.Patents cover Nu-3 topical gel formulation; Nu-3 is being advanced into a Phase 2 trial for mildly infected diabetic foot ulcers.Nu-3 gel formulation portfolio now totals 27 granted patents; overall IP estate totals 71 granted patents with 28 pending applications.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL1k5Vfk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637344005","title":"Lakewood-Amedex Q1 FY26 net loss widens to $923,291","url":"https://stock-news.laohu8.com/highlight/detail?id=2637344005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637344005?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:55","pubTimestamp":1779483358,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics posted a net loss of USD 923,291 for the quarter ended March 31, 2026, widening from USD 539,617 a year earlier.Operating loss widened to USD 886,750 as operating expenses rose to USD 886,750 from USD 542,609.General and administrative costs climbed to USD 704,603 from USD 372,906, driven by higher professional fees and investor relations spending tied to preparation for a proposed Nasdaq direct listing.Research and development spending edged up to USD 182,147 from USD 169,703, while net interest expense increased as interest expense rose to USD 38,219 from USD 1,315.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL8mw7NB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}